Emyria expands psychiatry advisory to advance psychedelic-assisted therapies

Latest News

Data-backed drug development and care delivery company Emyria (ASX:EMD) has announced the appointment of consultant psychiatrist Dr Jeremy Tannenbaum to its clinical advisory.

The company said Dr Tannenbaum will help advance its psychedelic-assisted research and related drug development programs.

Dr Tannenbaum’s interests and training covers the interface between psychiatry and pain medicine as well as the emerging use of psychedelic-assisted psychotherapy and other potential uses of psychedelics.

At the completion of further training, Dr Tannenbaum will be one of only a small number of specialist medical practitioners in Australia to hold dual qualifications in both psychiatry and pain medicine.

Emyria managing director Dr Michael Winlo said, “We’re delighted to welcome Dr Jeremy Tannenbaum to our world-class clinical advisory. Dr Tannenbaum has a unique combination of specialist training and research experience covering psychiatry, pain medicine and the use of psychedelic-assisted therapy to address major mental health concerns.

"We believe Dr Tannenbaum’s unique and diverse training in psychiatry and pain medicine can greatly advance Emyria’s MDMA-assisted psychotherapy trials for Post-Traumatic Stress Disorder, our MDMA-analogue discovery and screening program, and also support Emyria to evaluate the use of cannabinoid and other novel therapeutic approaches to address the biopsychosocial aspects of complex pain management.”

Dr Tannenbaum added, “Psychedelic-assisted therapy is showing great promise in treating complex and difficult-to-treat mental health conditions. In order to reach the patients most in need, further research and clinical evidence is required. I’m pleased to support Emyria’s unique model of care delivery, evidence generation and treatment development, which is well-placed to evaluate how best to deliver these treatments consistently and safely.”